Fosamax and Osteonecrosis of the Jaw: Understanding the Pathophysiology and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Occupational Risk Awareness

The legacy of general health and science communication has long emphasized the importance of informed decision-making regarding medications and their potential side effects. Within this broad context, public health messaging has historically focused on empowering individuals with knowledge about treatment benefits and risks, often framed around common conditions and widely prescribed therapies. This foundation of patient education and risk awareness provides a critical backdrop for understanding more specialized areas of pharmaceutical safety. Transitioning from this general health perspective, a more focused concern emerges when considering the occupational implications of exposure to certain medications. Specifically, the widespread use of bisphosphonates like Fosamax in clinical practice has prompted a shift in attention from patient-centered risk communication to the potential hazards faced by those who handle these substances in professional settings. The question of how such exposure might relate to adverse outcomes, such as osteonecrosis of the jaw, becomes a matter of occupational health. This pivot requires examining the pathways through which contact with the drug—whether during manufacturing, preparation, or administration—could pose risks distinct from those experienced by the patient taking the medication. Thus, the heritage of general health education now converges with a specialized inquiry into workplace safety and the mechanisms of exposure.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the occupational health perspective, it is essential to delve into the specific medication at the center of this concern: Fosamax (alendronate). Fosamax is a bisphosphonate approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section bridges the general risk awareness to the specific pathophysiology linking Fosamax to ONJ.

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The pathophysiology linking Fosamax to ONJ involves several mechanistic pathways. Bisphosphonates like alendronate accumulate in bone tissue, particularly at sites of high bone turnover such as the jaw. The jawbone exhibits unique structural and metabolic properties that may predispose it to complications from bisphosphonate therapy. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate treatment alters the mechanical and material properties of the jawbone, potentially contributing to ONJ development.

Clinical Presentation and Risk Factors

The clinical presentation of ONJ includes pain, swelling, infection, and exposed bone in the jaw. Diagnosis is based on clinical examination and imaging. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Temporal Considerations

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse effect, its incidence in clinical trials was not significantly different from placebo, indicating that other factors may contribute to its development. The timeline between exposure and documented harm can vary widely. ONJ has been reported in patients taking bisphosphonates, and the risk may increase with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For affected patients, establishing causation requires careful evaluation of their medical history, including duration of Fosamax use, presence of risk factors, and temporal relationship between drug initiation and ONJ onset.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) accumulates in bone tissue, particularly in the jawbone, which has high turnover. It alters the mechanical and material properties of the jawbone, impairing bone remodeling and leading to non-healing bone exposure. Studies have shown changes in tissue mineral density and nanoindentation properties in animal models (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities like periodontal disease, anemia, coagulopathy, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk increases with longer duration of bisphosphonate use.

How long does it take for osteonecrosis of the jaw to develop after starting Fosamax?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, and some have recurrence upon rechallenge.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.